MOB2 Inhibitors
MOB2 inhibitors primarily focus on the Hippo signaling pathway, a crucial regulator of tissue growth and cell proliferation. Within this cascade, MOB2, as a part of the MOB kinase activator family, plays a subtle but critical role. Most compounds, such as Verteporfin, XMU-MP-1, and Dasatinib, indirectly influence MOB2 by targeting other pivotal components in the pathway. Verteporfin, for instance, impedes the interaction between YAP and TEAD, crucial transcription factors in the Hippo pathway, thereby inhibiting the activation of specific genes that influence cell behavior.
Furthermore, chemicals like LPA and S1P act on G-protein coupled receptors (GPCRs), known to suppress the Hippo pathway. Their action, though a level removed, has implications for the MOB2-associated signaling cascade. Moreover, some compounds, including Lovastatin and other statin drugs, exhibit dual functionality. While their primary role lies in cholesterol regulation, their influence over the Hippo pathway, particularly on YAP/TAZ, is noteworthy.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verteporfin | 129497-78-5 | sc-475698 sc-475698A | 10 mg 100 mg | $354.00 $2764.00 | 5 | |
YAP-TEAD interaction inhibitor, which in the Hippo pathway is downstream of MOB2. By blocking this interaction, the activation of genes involved in proliferation and survival is inhibited. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor. Src kinases can activate YAP in the Hippo pathway, influencing the MOB2-associated signaling cascade. | ||||||
Doxycycline Hyclate | 24390-14-5 | sc-204734B sc-204734 sc-204734A sc-204734C | 100 mg 1 g 5 g 25 g | $27.00 $50.00 $105.00 $194.00 | 25 | |
Inhibits MST1, a kinase in the Hippo pathway, and can subsequently modulate downstream signaling involving MOB2. | ||||||
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
GPCR activator known to suppress the Hippo pathway. While activating the pathway, it indirectly reduces the inhibitory action on YAP and TAZ, affecting MOB2 interactions. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
HMG-CoA reductase inhibitor that can suppress YAP/TAZ in the Hippo pathway. By affecting YAP/TAZ, upstream signaling involving MOB2 can be modulated. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Another GPCR activator suppressing the Hippo pathway and indirectly affecting MOB2's role in the pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor which can upregulate YAP in the Hippo pathway. By influencing YAP, the upstream interactions involving MOB2 can be modulated. | ||||||
D-erythro-Sphingosine-C19 | 31148-92-2 | sc-474288 | 10 mg | $354.00 | ||
A YAP-TEAD interaction inhibitor, disrupting the downstream effects in the Hippo pathway and potentially influencing MOB2's interactions. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Inhibits actin polymerization, which can lead to YAP phosphorylation and its retention in the cytoplasm, indirectly affecting MOB2’s role in the Hippo pathway. | ||||||